Portage Biotech Inc - Asset Resilience Ratio
Portage Biotech Inc (PRTG) has an Asset Resilience Ratio of 0.00% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Portage Biotech Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2021)
This chart shows how Portage Biotech Inc's Asset Resilience Ratio has changed over time. See PRTG total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Portage Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Portage Biotech Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Portage Biotech Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Portage Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Portage Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Portage Biotech Inc (2000–2021)
The table below shows the annual Asset Resilience Ratio data for Portage Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-03-31 | 0.00% | $0.00 | $174.86 Million | -- |
| 2020-03-31 | 0.04% | $68.00K | $173.17 Million | -0.02pp |
| 2019-03-31 | 0.06% | $103.00K | $173.72 Million | -0.46pp |
| 2018-03-31 | 0.52% | $52.00K | $10.00 Million | -97.83pp |
| 2017-03-31 | 98.35% | $58.91 Million | $59.90 Million | +95.31pp |
| 2012-03-31 | 3.04% | $228.12K | $7.51 Million | -17.29pp |
| 2011-03-31 | 20.32% | $1.96 Million | $9.62 Million | +7.27pp |
| 2010-03-31 | 13.05% | $1.33 Million | $10.22 Million | -55.48pp |
| 2009-03-31 | 68.52% | $864.47K | $1.26 Million | -0.83pp |
| 2008-03-31 | 69.36% | $3.53 Million | $5.09 Million | +19.67pp |
| 2007-03-31 | 49.69% | $2.87 Million | $5.78 Million | +17.07pp |
| 2006-03-31 | 32.62% | $1.53 Million | $4.68 Million | +31.11pp |
| 2005-03-31 | 1.51% | $63.15K | $4.20 Million | -25.91pp |
| 2000-03-31 | 27.42% | $480.04K | $1.75 Million | -- |
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor … Read more